The laboratory of Dr. Taosheng Chen studies the roles of nuclear receptors PXR and CAR and the CYP3A subfamily of drug–metabolizing enzymes in regulating drug-induced liver toxicity, tumorigenesis, and cancer drug resistance. We develop novel chemical probes/therapeutic leads by using a multidisciplinary approach (biology, chemistry and structural biology), and use them to interrogate the function of PXR, CAR and CYP3A in order to overcome drug toxicity, drug resistance and tumorigenesis in cellular and animal models (Lin et al, Nat Commun. 8:741, 2017).
The postdoctoral fellow will investigate the molecular mechanisms responsible for the aberrant expression of CYP3A in extrahepatic cancers (possible mechanisms involve transcription and/or alternative splicing, both independent of and dependent on PXR).
The successful candidate will work in a collaborative and multidisciplinary environment by collaborating with biologists, chemists and structural biologists (https://www.stjude.org/chen).
Highly motivated individuals with a strong publication record or other evidence of scientific accomplishment are encouraged to apply. Expertise in cell and molecular biology and significant experience in regulation of gene transcription and splicing are desirable. Candidates must have (or soon receive) a PhD or MD degree.
Taosheng Chen, PhD
Member (Professor), Department of Chemical Biology and Therapeutics
St. Jude Graduate School of Biomedical Sciences
Director, High Throughput Bioscience Center
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-2794